Cytokinetics
CYTK • NASDAQ
Cytokinetics is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Robert I. Blum, with a market cap of $7.7B.
CEORobert I. Blum
Next Earnings
Upcoming earnings announcement for Cytokinetics
Date
Tuesday, May 5, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$1.64
Revenue Estimate
$8.3M
Earnings History
Past 12 earnings reports for Cytokinetics
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 24, 2026 | Q4 2025 | -$1.50Est: -$1.41 | -6.4% | $17.8MEst: $6.4M | +178.7% |  10-K |
| Nov 5, 2025 | Q3 2025 | -$1.54Est: -$1.58 | +2.5% | $1.9MEst: $5.9M | -66.9% | 10-Q |
| Aug 7, 2025 | Q2 2025 | -$1.12Est: -$1.35 | +17.0% | $66.8MEst: $2.8M | +2319.3% | 10-Q |
| May 6, 2025 | Q1 2025 | -$1.36Est: -$1.36 | 0.0% | $1.6MEst: $2.6M | -39.5% | 10-Q |
| Feb 27, 2025 | Q4 2024 | -$1.26Est: -$1.17 | -7.7% | $16.9MEst: $14.3M | +18.7% | 10-K |
| Nov 6, 2024 | Q3 2024 | -$1.36Est: -$1.26 | -7.9% | $463.0KEst: $1.2M | -61.3% | 10-Q |
| Aug 8, 2024 | Q2 2024 | -$1.31Est: -$1.06 | -23.6% | $249.0KEst: $920.0K | -72.9% | 10-Q |
| May 8, 2024 | Q1 2024 | -$1.33Est: -$1.14 | -16.7% | $835.0KEst: $900.0K | -7.2% | 10-Q |
| Feb 27, 2024 | Q4 2023 | -$1.38Est: -$0.97 | -42.3% | $1.7MEst: $10.8M | -84.5% | 10-K |
| Nov 2, 2023 | Q3 2023 | -$1.35Est: -$0.74 | -82.4% | $378.0KEst: $20.2M | -98.1% | — |
| Aug 3, 2023 | Q2 2023 | -$1.34Est: -$1.23 | -8.9% | $867.0KEst: $2.5M | -65.3% | 10-Q |
| May 4, 2023 | Q1 2023 | -$1.38Est: -$1.20 | -15.0% | $4.6MEst: $2.1M | +120.7% | — |